Premium
Progression of dysautonomia in multiple system atrophy: a prospective study of self‐perceived impairment
Author(s) -
Köllensperger M.,
StampferKountchev M.,
Seppi K.,
Geser F.,
Frick C.,
Del Sorbo F.,
Albanese A.,
Gurevich T.,
Giladi N.,
Djaldetti R.,
Schrag A.,
Low P. A.,
Mathias C. J.,
Poewe W.,
Wenning G. K.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2006.01554.x
Subject(s) - dysautonomia , medicine , quality of life (healthcare) , atrophy , disease , physical therapy , nursing
To assess severity and progression of self‐perceived dysautonomia and their impact on health‐related quality of life (Hr‐QoL) in multiple system atrophy (MSA), twenty‐seven patients were recruited by the European MSA Study Group (EMSA‐SG). At baseline, all patients completed the Composite Autonomic Symptom Scale (COMPASS) and the 36 item Short Form Health Survey (SF‐36), and they were assessed using the 3‐point global disease severity scale (SS‐3) and the Unified MSA Rating Scale (UMSARS). After 6 months follow‐up, the self completed COMPASS Change Scale (CCS), the SF‐36, SS‐3, and UMSARS were obtained. MSA patients showed marked self‐perceived dysautonomia at baseline visit and pronounced worsening of dysautonomia severity on the CCS at follow‐up. Severity and progression of dysautonomia did not correlate with age, disease duration, motor impairment and overall disease severity at baseline. There were no significant differences between genders and motor subtypes. Baseline COMPASS scores were, however, inversely correlated with SF‐36 scores. Progression of self‐perceived dysautonomia did not correlate with global disease progression. Hr‐QoL scores were stable during follow‐up. This is the first study to investigate self‐perceived dysautonomia severity in MSA and its evolution over time. Our data suggest that dysautonomia should be recognized as a key target for therapeutic intervention in MSA.